Dr. Peter Schmid reports on key results from ESMO 2018 Congress: LBA1_PR: IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in treatment-naive, locally advanced or metastatic triple-negative breast cancer.
ESMO 2018 Congress: Highlights in metastatic triple negative breast cancer LBA1 PR